and Amgen's bispecific antibody Blincyto (blinatumomab) for CD19-positive ALL. It is also a potential rival to Incyte/MorphoSys' CD19-targeting antibody Minjuvi (tafasitamab) - approved last ...

eDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA fDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA ...

Meanwhile, Amgen's bispecific antibody Blincyto (blinatumomab) also targets CD19 but is indicated for acute lymphoblastic leukaemia (ALL). CAR-Ts can be highly effective but are made by harvesting ...

Tumour biomarkers is a term used to describe many different potential markers of cancer development and progression. These markers can come in many forms for example, proteins, biochemicals ...

Progression-free survival significantly lower with fixed-duration acalabrutinib-venetoclax with or without obinutuzumab. HealthDay News — For patients with previously untreated chronic ...